Amorfix presents vCJD blood test results from its commercial high-throughput platform

---

Amorfix Life Sciences announces that Dr. Neil Cashman, chief scientific officer of Amorfix, presented an overview of the company's proprietary Epitope Protection (EP) technology for the in vitro detection of variant Creutzfeldt-Jacob Disease (vCJD) at the Transmissible Spongiform Encephalopathies (TSE) Conference held in Berlin, Germany.

The presentation entitled, "Detection of vCJD prions in blood using epitope protection" highlighted the sensitivity and specificity of the EP-vCJD(TM) high-throughput diagnostic test for screening blood donations.

"The blood transfusion services in Europe need a screening test to protect the blood supply from transmission of vCJD. This conference provided an opportunity to showcase and increase the awareness of our proprietary EP-vCJD(TM) diagnostic test with the European blood agencies and regulatory authorities," said Dr. George Adams, CEO of Amorfix Life Sciences. "Our test kits are now available for research purposes which allows for its use for prevalence studies to assess the number of people that have vCJD and the risk of blood transfusion in regions where contaminated beef was consumed."